Fulgent Genetics, Inc. FLGT

The latest update on Fulgent Genetics centers on a higher analyst price target, with fair value moving from US$15 to US$19. That shift reflects refreshed views on profitability and valuation, while the Neutral rating signals that analysts see both upside potential and execution risk in balance for now. As you read on, you will see how this new target fits into the broader narrative around Fulgent Genetics and what to watch as the story develops from here. Stay updated as the Fair Value for...

Moby summary of Fulgent Genetics, Inc.'s Q2 2026 earnings call

Despite billing system transition challenges and revised guidance, Fulgent Genetics advances its clinical pipeline and expands its AI-driven diagnostics portfolio.

EL MONTE, Calif., July 30, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026.

EL MONTE, Calif., July 09, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questi

The latest price target update for Fulgent Genetics keeps the model fair value at US$15.00, signaling that analysts are not making a major shift to the core valuation framework. Instead, the change reflects fresh commentary on how the current share price lines up with updated expectations around execution risk and what investors are prepared to pay for future earnings. As you read on, you will see how this evolving narrative fits with recent guidance, clinical news, and what it may mean for...

Fulgent Genetics enters this update cycle with no changes to its price targets, leaving the existing analyst expectations intact for now. Even without new signals on where analysts think the stock could head next, you can still track what this steady stance might mean for your own view of the company. Read on to see how to keep up with the evolving narrative around Fulgent Genetics and where to look as fresh information comes through. Stay updated as the Fair Value for Fulgent Genetics shifts...

EL MONTE, Calif., June 01, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

Despite a dip in revenue, Fulgent Genetics Inc (FLGT) focuses on strategic acquisitions and pipeline advancements to bolster future growth.

Moby summary of Fulgent Genetics, Inc.'s Q1 2026 earnings call

Fulgent Genetics (NASDAQ:FLGT) reported first-quarter 2026 revenue of $71.1 million as the company worked through a planned decline in testing volumes from its largest customer while integrating the recently completed acquisitions of Bako Diagnostics and StrataDX. First-quarter revenue pressured by